Myriad Genetics (MYGN) Addresses HIPAA Complaint; Believes it 'Acted Appropriately'

Go back to Myriad Genetics (MYGN) Addresses HIPAA Complaint; Believes it 'Acted Appropriately'

Myriad Genetics’ Statement on HIPAA Complaint from Four Patients

May 19, 2016 4:56 PM EDT

SALT LAKE CITY, May 19, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results.  The Company believes it has complied with these requests and provided these four patients with their designated record set and... More